SPXT:ARCA-ProShares S&P 500 Ex-Technology

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 55.708

Change

-0.03 (-0.06)%

Market Cap

USD 2.22M

Volume

100.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks investment results, before fees and expenses that track the performance of the S&P 500? Ex-Information Technology & Telecommunication Services Index (the "index"). Under normal circumstances, the fund will invest at least 80% of its total assets in component securities. The index seeks to provide exposure to the companies of the S&P 500? Index (the "S&P 500?") with the exception of those companies included in the Information Technology and the Telecommunication Services Sectors (collectively, the "Technology Sector").

Inception Date: 22/09/2015

Primary Benchmark: S&P 500 Ex-Infor Tech USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.27%

Management Expense Ratio: 0.27 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing SPXT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.86% 50% F 65% D
Dividend Return 0.95% 65% D 19% F
Total Return 17.81% 50% F 62% D
Trailing 12 Months  
Capital Gain 5.55% 53% F 62% D
Dividend Return 1.39% 65% D 26% F
Total Return 6.94% 53% F 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 6.27% 61% D- 70% C-
Dividend Return 7.46% 61% D- 65% D
Total Return 1.19% 71% C- 27% F
Risk Return Profile  
Volatility (Standard Deviation) 7.00% 97% N/A 84% B
Risk Adjusted Return 106.58% 92% A 91% A-
Market Capitalization 2.22M 16% F 3% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.